University of Antwerp
Prinsstraat 13, Antwerpen, 2000, Belgium
Overview
UAntwerpen The University of Antwerp (Universiteit Antwerpen) is a young and dynamic Belgian university. It is characterised by its high standards in education, internationally competitive research and entrepreneurial approach. It was founded in 2003 after the merger of the three universities of Antwerp. The university's roots go back to 1852. The University of Antwerp has 9 faculties and several autonomous, faculty-like institutes. Doctoral programmes are available in all faculties, with more than 20,109 students (+1,479 PhD students) registered. In total the university has over 4.987 staff members. The University of Antwerp hosts 5 centres of excellence Nanostructures, Molecular Neurogenetics, Environmental Studies, Social Policy, Evaluation of Vaccination Education is student-centred and competency-based. Students are stimulated to develop into independently minded people who are capable of thinking analytically. The University of Antwerp has adopted the bachelor-master structure. It offers 3-year Bachelor programmes (180 ECTS credits) and 1-year or 2-year Master programmes (60 or 120 ECTS credits). The university is part of the Antwerp University Association (AUHA), a regional association with the university and 3university colleges for professional education.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 8
Investment portfolio
- Aloxy
Participated · Equity · Jun 2022
Aloxy develops plug-and-play Industrial IoT technology and a valve monitoring system combining wireless sensors (LPWAN/LoRaWAN) with its Aloxy IIoT Hub platform to manage device fleets and feed sensor data to clients. Launched as a 2018 spin-off from imec and the University of Antwerp, the company focuses on chemical and energy customers, with early demand from Europe followed by the US and interest in South America and Asia. Product offerings include an annual valve monitoring system and continued prototyping of Aloxy.Connect to integrate PT100 temperature and 4-20 mA probes. Planned product work includes launching Ex-certified (explosion-proof) wireless sensors and expanding the Aloxy IIoT Hub to support third-party sensors and multiple network protocols. The company is pursuing certifications including ISO27001 and country-specific Ex certifications to accelerate industrial adoption. Aloxy says it will grow its European and US sales teams as part of its scale-up strategy.
- Multiplicom
Participated · Series A · Apr 2011
Multiplicom NV develops, produces and sells genetic tests based on innovative molecular diagnostic technologies. Formed in 2010 as a spin-off of the University of Antwerp and VIB, the company is led by CEO Dirk Pollet and is based in Niel, Belgium. Its tests are used to identify increased genetic risk for disease, detect congenital defects early, and help select the most suitable therapies for patients. Multiplicom received CE certification in 2012 for a test that detects genetic defects indicating increased risk of ovarian or breast cancer. For research applications it sells kits for cystic fibrosis, bowel cancer, heart failure, kidney disease and muscle disease. In 2013 the company planned to introduce a new series of kits to detect DNA mutations in cancerous tissue. Multiplicom is a molecular diagnostics company spun out of the Jurgen Del-Favero lab at VIB and the University of Antwerp where its core Multiplexer™ technology was developed. The company develops, manufactures and commercializes molecular genetic tests that assess genetic disease risk, enable early detection of congenital defects, and help identify appropriate therapies. Led by CEO Dirk Pollet, Multiplicom focuses initially on direct sales in Western European countries while appointing distributors elsewhere. The company intends to use new funding to develop innovative diagnostic tests, secure CE-marking for assays, and build a sales network across the European Union. Multiplicom is based in Niel, Belgium and targets commercialization of its diagnostic assays in the EU market.